Insulin Delivery Devices Market

Insulin Delivery Devices Market Size

The global insulin delivery devices market was valued at USD 22.8 billion in 2024. The market is expected to grow from USD 25.2 billion in 2025 to USD 61.6 billion in 2034, at a CAGR of 10.4% during the forecast period, according to the latest report published by Global Market Insights Inc. The insulin delivery device market is witnessing robust growth, driven by the rising prevalence of diabetes, continuous technological innovation, and increasing awareness around self-management of the condition. The demand for user-friendly, portable, and precise insulin delivery solutions such as insulin pens, pumps, and patch devices is expanding rapidly, as patients seek more convenient and effective ways to manage their glucose levels.

This market segment plays a critical role in enhancing treatment adherence and enabling personalized diabetes care across diverse patient populations. Leading companies such as Novo Nordisk A/S, Ypsomed Holdings AG, Medtronic plc, Tandem Diabetes Care, and Sanofi are at the forefront of this industry. These players maintain their competitive edge through continuous innovation in device technology, strategic partnerships, and strong global distribution networks, all aimed at improving patient outcomes and simplifying diabetes management.

Insulin delivery devices market is witnessing sharp growth, growing from USD 17.2 billion in 2021 to USD 20.7 billion in 2023. The expansion of the market is triggered by the increase in global diabetes prevalence. Based on the World Health Organization (WHO) report in 2024, the number of diabetic individuals rose from 200 million in 1990 to 830 million in 2022. Its spread has been increasing more quickly in low- and middle-income nations compared to high-income countries. Diabetes, in 2021, was the direct reason behind 1.6 million deaths, with 47% of them happening before the age of 70. The rise in cases has dramatically increased demand for easy-to-use and efficient insulin delivery systems.  

Moreover, increasing initiatives by global health organizations and national governments are contributing significantly to the growth of the insulin delivery devices market. The World Health Organization (WHO) launched the Global Diabetes Compact with a vision to reduce the risk of diabetes and ensure equitable, comprehensive, affordable, and quality treatment for all diagnosed individuals. As part of this program, WHO has outlined five global coverage targets to be achieved by 2030, aimed at improving diagnosis, treatment, and access to essential diabetes care. These efforts, along with growing regulatory support and public-private collaborations, are driving the adoption of insulin delivery devices worldwide.

Insulin delivery devices are medical tools designed to administer insulin to individuals with diabetes in a safe, accurate, and convenient manner. These devices play a critical role in diabetes management by helping patients maintain optimal blood glucose levels, especially when the body is unable to produce sufficient insulin naturally.

Insulin Delivery Devices Market Trends

• The global insulin delivery device market is undergoing a transformative evolution, driven by the rising burden of diabetes and the growing demand for convenient, accurate, and patient-friendly solutions. As more individuals transition toward self-management of diabetes, devices such as insulin pens, pumps, and patch systems are becoming preferred alternatives to traditional syringes due to their ease of use and improved dosing precision.
  
• Technological innovation is a key catalyst for market growth. Companies are continuously enhancing device design to improve comfort, safety, and usability. Features such as ergonomic grips, prefilled cartridges, and automated dosing mechanisms are helping reduce user error and improve treatment adherence. The integration of digital diabetes management technologies including Bluetooth connectivity and mobile app integration is offering patients and healthcare providers real-time access to insulin therapy data, enabling more personalized and efficient care.
  
• For instance, Insulet Corporation’s Omnipod DASH Insulin Management System, approved by the U.S. FDA, exemplifies this trend. It features bluetooth-enabled connectivity and a personal diabetes manager, allowing seamless access to therapy information via smartphone apps such as Omnipod Display and Omnipod View. These innovations are reshaping how patients interact with their treatment regimens.
  
• Emerging markets in Asia-Pacific, Latin America, and Africa are becoming increasingly influential. Rising diabetes prevalence, improving healthcare infrastructure, and growing awareness of modern diabetes care are creating fertile ground for market expansion. Local manufacturing and strategic partnerships are helping companies penetrate these regions more effectively, while also addressing affordability concerns.
  

Insulin Delivery Devices Market Analysis

In 2021, the global market was valued at USD 17.2 billion. The following year, it saw a slight increase to USD 18.8 billion, and by 2022, the market further climbed to USD 20.7 billion in 2023.

Based on product, the global insulin delivery devices market is divided into insulin delivery devices and consumables. The insulin delivery devices segment accounted for 73.5% of the market in 2024 primarily due to their technological sophistication, long-term usability, and growing preference among patients and healthcare providers. The segment is expected to exceed USD 45.1 billion by 2034, growing with the fastest CAGR of 10.4% during the forecast period. On the other hand, consumables segment is expected to grow with slightly higher CAGR of 10.5%. The growth of this segment is primarily driven by the recurring demand for essential components such as insulin cartridges, infusion sets, reservoirs, and needles.

• The device segment is the leading part of the global insulin delivery device market, holding a major share thanks to its advanced technology, long-term usability, and strong patient preference. This segment is further divided into insulin delivery devices, which include insulin pens, pumps, and others each designed to make insulin administration more accurate, convenient, and user-friendly.
  
• These devices are popular because they’re easy to use, portable, and often connect with digital health platforms, making them ideal for both patients and healthcare professionals. They help people manage their diabetes more independently, reduce mistakes in dosing, and improve overall treatment results.
  
• Innovation is a key growth driver in this segment. Companies are focusing on features such as automated dosing, Bluetooth connectivity, and comfortable designs to make insulin delivery simpler and more effective. For example, Novo Nordisk’s NovoPen 6 and NovoPen Echo Plus are smart insulin pens that automatically track doses and connect to diabetes apps, helping patients and doctors monitor treatment more easily.
  
• These improvements are especially useful in clinical and home settings, where reliability and ease of use are essential. Devices are also being designed for specific groups such as children, older adults, and people with limited hand movement, making them more accessible to a wider range of users.
  

Based on end use, insulin delivery devices market is classified into hospitals and clinics, home care, and other end users. The home care segment dominated the market in 2024 and is expected to reach USD 30.7 billion by 2034.

• The home care segment is emerging as a key growth area in the insulin delivery device market, driven by rising patient preference for managing diabetes in familiar, comfortable settings. This shift is supported by the availability of user-friendly devices, growing awareness around self-management, and facilitative policies introduced by public health organizations.
  
• Patients are increasingly opting for portable and easy-to-use insulin delivery devices that simplify daily administration and reduce the need for frequent hospital visits. Devices such as disposable insulin pens and wearable pumps are particularly popular in-home settings due to their convenience, minimal training requirements, and reliable performance.
  
• Public initiatives are playing a major role in this trend. For example, the American Diabetes Association’s Diabetes Self-Management Support (DSMS) program and the Diabetes Support Initiative aim to educate and empower patients to manage their condition independently. Similarly, the Building Community Supports for Diabetes Care initiative promotes home-based care to reduce healthcare costs and improve patient comfort.
  
• As a result, demand for insulin delivery devices suited for home use is rising steadily. These devices not only improve treatment adherence but also align with broader healthcare goals of cost reduction, patient empowerment, and decentralized care delivery. Manufacturers are responding by designing products that are intuitive, hygienic, and compatible with digital monitoring tools, making them ideal for home-based diabetes management.  
  

North America Insulin Delivery Devices Market

• North America remains the leading region in the global insulin delivery devices industry, driven by high diabetes prevalence, advanced healthcare infrastructure, and strong regulatory support. According to the American Diabetes Association, in 2021, 38.4 million Americans or 11.6% of the population had diabetes. Of these, 2 million Americans had type 1 diabetes, including approximately 304,000 children and adolescents. This substantial patient base drives consistent demand for insulin delivery devices across all age groups.
  
• The region’s healthcare systems prioritize precision, safety, and ease of use, making insulin pens a preferred choice for both inpatient and outpatient diabetes management. Hospital pharmacies, retail chains, and e-commerce platforms ensure wide accessibility, while insurance coverage and formulary inclusion further support adoption.
  
• North America also benefits from a well-defined regulatory framework, with agencies such as the U.S. FDA ensuring high standards for device safety and efficacy. This enables faster commercialization of new insulin delivery devices technologies and supports early adoption of improved delivery formats.
  
• The economic impact of diabetes care is significant, with the total cost of diagnosed diabetes in the U.S. reaching USD 412.9 billion in 2022. This underscores the importance of efficient, scalable, and patient-friendly solutions in managing long-term treatment costs and improving health outcomes.
  

The U.S. insulin delivery devices market was valued at USD 5.6 billion and USD 6.1 billion in 2021 and 2022, respectively. The market size reached USD 7.4 billion in 2024, growing from USD 6.7 billion in 2023.

• The U.S. market is driven by a high diabetes burden and strong institutional infrastructure for chronic disease management. According to the Centers for Disease Control and Prevention (CDC), 8.7 million adults aged 18 years or older met laboratory criteria for diabetes but were unaware.
  
• This significant undiagnosed population highlights the need for accessible and easy-to-use insulin delivery solutions.
  
• Diabetes was the eighth leading cause of death in the U.S. in 2021, based on 103,294 death certificates listing it as the underlying cause. It was mentioned in a total of 399,401 certificates, underscoring the severity of the disease and the importance of effective treatment tools.
  
• Hospitals, clinics, and retail pharmacies across the U.S. are well-equipped to support insulin delivery devices distribution, with formulary inclusion and insurance coverage facilitating widespread access. The structured healthcare system enables consistent patient education and follow-up, supporting long-term adherence to insulin therapy.
  

Europe Insulin Delivery Devices Market

Europe market accounted for USD 6.5 billion in 2024 and is anticipated to show lucrative growth over the forecast period.

• Europe stands out as a critical region in the global insulin delivery devices industry, driven by its advanced healthcare infrastructure, strong regulatory frameworks, and growing burden of diabetes. According to the International Diabetes Federation, the number of adults aged 20-79 years living with diabetes in the European Region (EUR) was 65.6 million in 2024, and is projected to reach 72.4 million by 2050, marking a 10% increase.
  
•  The region also has the highest number of people with type 1 diabetes globally, 2.7 million individuals, further emphasizing the need for effective and user-friendly insulin delivery solutions. The estimated diabetes prevalence of 9.8% highlights the urgency for scalable and efficient treatment options.
  
• Europe’s emphasis on digital health integration and chronic disease management supports the adoption of insulin delivery devices. These innovations align with broader healthcare trends in the region, including precision medicine, remote monitoring, and patient-centric care.
  

Germany dominates the European insulin delivery devices market, showcasing strong growth potential.

• Germany represents a significant segment of the European market, supported by its large diabetic population, advanced healthcare infrastructure, and commitment to chronic disease management. As one of the 59 countries in the International Diabetes Federation (IDF) EUR Region, Germany plays a central role in shaping regional trends in diabetes care and insulin delivery technologies.
  
• In 2021, Germany had a total adult population of 62 million, with a diabetes prevalence of 10%, amounting to 6.2 million adults living with diabetes. This number rose to 6.5 million in 2024.
  
• Moreover, Germany’s leadership in medical device innovation, patient education, and digital health integration positions it as a fertile ground for growth in both standard and smart insulin pens, which was valued at USD 850.6 million in 2023.
  
• The country’s emphasis on precision medicine, data-driven care, and patient-centric solutions aligns with the evolving needs of diabetic patients, especially those requiring long-term insulin therapy.
  

Asia Pacific Insulin Delivery Devices Market

The Asia Pacific market is anticipated to grow at the highest CAGR during the analysis timeframe.

• The Asia Pacific region is emerging as a critical growth market for insulin delivery devices, driven by a rapidly rising diabetes burden, large population base, and increasing healthcare investments. According to the International Diabetes Federation (IDF), the number of adults aged 20-79 years with diabetes in the South-East Asia (SEA) Region was 106.9 million in 2024 and is projected to reach 184.5 million by 2050, a staggering 73% increase. Over the same period, the prevalence of diabetes is expected to rise by 36%. 
  
• This sharp rise in diabetes cases across countries such as India, Indonesia underscores the urgent need for scalable, efficient, and patient-friendly insulin delivery solutions.
  

China insulin delivery devices market is estimated to grow with a significant CAGR, in the Asia Pacific market.

• China is a cornerstone of the global insulin delivery devices industry, owing to its large diabetic population, rapid healthcare modernization, and growing emphasis on chronic disease management. As one of the 38 countries and territories in the IDF Western Pacific Region, China plays a dominant role in shaping regional diabetes trends.
  
• In 2024, China had a total adult population of over 1.07 billion, with a diabetes prevalence of 11.9%, amounting to nearly 148 million adults living with diabetes. This makes China the largest national diabetes population globally, and a key market for insulin delivery solutions. By 2050, the number of people with diabetes in the Western Pacific Region is projected to rise from 215 million to 254 million, reinforcing the urgency for scalable and efficient treatment options.
  

Latin American Insulin Delivery Devices Market

Brazil leads the Latin American market, exhibiting remarkable growth during the analysis period.

• Brazil is a leading market for insulin delivery devices in the Latin America Region, driven by its high diabetes prevalence, expanding healthcare access, and growing demand for chronic disease management tools. As one of the 19 countries in the IDF SACA Region, Brazil plays a pivotal role in shaping regional trends in diabetes care.
  
• In 2024, Brazil had a total adult population of over 155 million, with a diabetes prevalence of 10.6%, amounting to 16.6 million adults living with diabetes. This makes Brazil one of the largest national diabetes populations in Latin America. By 2050, the number of people with diabetes in the SACA Region is projected to rise from 35 million to 52 million.   
  
• Brazil’s healthcare system is increasingly adopting modern insulin delivery technologies, including smart insulin pens that offer digital dose tracking, reminders, and integration with mobile health platforms. These innovations are particularly valuable in improving treatment adherence and glycemic control, especially in underserved and rural populations.
  

Middle East and Africa Insulin Delivery Devices Market

Saudi Arabia insulin delivery devices industry to experience substantial growth in the Middle East and Africa market in 2024.

• Saudi Arabia is a key market for insulin delivery devices, driven by its exceptionally high diabetes prevalence, expanding healthcare infrastructure, and government-led health initiatives. As one of the 21 countries and territories in the IDF MENA Region, Saudi Arabia plays a central role in shaping regional diabetes care strategies.
  
• In 2024, Saudi Arabia had a total adult population of nearly 25 million, with a diabetes prevalence of 23.1%, amounting to 5.34 million adults living with diabetes. This is one of the highest national prevalence rates globally, underscoring the urgent need for effective and accessible insulin delivery solutions. By 2050, the number of people with diabetes in the MENA Region is projected to nearly double, rising from 85 million to 163 million.
  
• Saudi Arabia’s healthcare system is undergoing rapid transformation under Vision 2030, which includes major investments in digital health, chronic disease management, and medical device innovation. Insulin pens, especially smart pens that offer dose tracking, reminders, and app integration are increasingly adopted to improve treatment adherence and glycemic control.
  
• The country’s growing interest in telemedicine, e-pharmacies, and mobile health units is also enhancing access to insulin therapies, especially in remote and underserved areas. These developments align with broader goals of personalized care, preventive medicine, and technology-driven healthcare delivery.   
  

Insulin Delivery Devices Market Share

The insulin delivery devices industry is characterized by a blend of established global leaders and emerging regional players, resulting in a moderately consolidated yet increasingly competitive landscape. Novo Nordisk leads the market with the highest share, followed by other key players such as Eli Lilly, Sanofi, Medtronic, and Ypsomed. Collectively, these five companies account for a significant portion of the global market at 64%, driven by their strong product portfolios, global distribution networks, and continuous investment in innovation.

To strengthen their market positions, leading firms are adopting multi-pronged strategies including acquisitions, partnerships, and competitive pricing. These efforts aim to make insulin pens more accessible and cost-effective, while also addressing unmet clinical needs in both developed and emerging markets. In addition to these dominant players, companies such as Owen Mumford, Medtronic, Biocon Biologics are contributing to the market’s growth through technological innovation, precision delivery systems, and region-specific strategies. Their presence is particularly notable in Asia Pacific, Latin America, and the Middle East, where rising diabetes prevalence and expanding healthcare infrastructure are driving increased adoption of insulin delivery solutions.

Overall, the market is witnessing intensified competition and greater diversity, as both established and emerging players continue to evolve their offerings and strategies to meet the global demand for effective and efficient insulin pen devices.

Insulin Delivery Devices Market Companies

Prominent players operating in the insulin delivery devices industry are as mentioned below:

• B. Braun Melsungen AG
• Becton, Dickinson and Company
• Biocon
• Debiotech S.A.
• Dongbao Pharmaceutical
• Eli Lilly & Company
• F. Hoffmann-La Roche Ltd.
• Gan & Lee Pharmaceuticals
• Haselmeier
• Insulet Corporation
• Julphar
• Lenomed Medical
• Medtronic plc
• MicroPort
• Nipro Corporation
• Novo Nordisk
• Owen Mumford
• Sanofi
• Scientific Corporation
• Suzhou Peng Ye Medical Devices
• Tandem Diabetes Care
• Terumo Corporation
• ViCentra B.V.
• Wockhardt Ltd.
• Ypsomed Holdings
  
• Ypsomed

Ypsomed is a key contributor to the insulin delivery devices market, known for its focus on self-administration technologies and patient-centric solutions. The company offers a diverse range of customizable delivery systems and maintains strong partnerships with leading pharmaceutical firms. Ypsomed’s emphasis on sustainability, usability, and global expansion supports its growing influence across both mature and emerging healthcare markets.

• Medtronic plc

Medtronic is a prominent player in the insulin delivery devices market, recognized for its long-standing expertise in diabetes care and medical technology. The company’s global presence, commitment to innovation, and focus on integrated care solutions have positioned it as a leader in delivering effective and reliable insulin delivery systems. Medtronic continues to invest in expanding access and improving patient outcomes through strategic collaborations and technology-driven approaches.

• Owen Mumford

Owen Mumford plays a vital role in the insulin delivery devices market through its innovative and ergonomic injection solutions. The company is recognized for its commitment to accessibility, comfort, and environmental responsibility. With a growing presence in emerging regions and a focus on affordability, Owen Mumford continues to support broader access to insulin therapies and enhances the overall patient experience.

Insulin Delivery Devices Industry News

• In December 2022, Amalgam Rx Inc., a digital health company specializing in software as a medical device (SaMD), expanded its global partnership with Novo Nordisk to commercialize the Dose Check app. The app was designed to support insulin initiation and titration for individuals with type 2 diabetes. Under the enhanced agreement, Dose Check was integrated with connected insulin delivery devices, continuous glucose monitors, and electronic health records. Novo Nordisk also made a strategic equity investment in Amalgam Rx, reinforcing their joint commitment to advancing personalized diabetes care through innovative digital solutions.
  
•  In August 2021, Eli Lilly and Company received FDA approval for the use of its rapid-acting insulin Lyumjev with Insulet Corporation’s Omnipod and Omnipod DASH insulin management systems. This approval expanded Lyumjev’s label to include administration via continuous subcutaneous insulin infusion (CSII) using insulin pumps. The collaboration between Eli Lilly and Insulet aimed to offer more flexible and efficient insulin delivery options for adults with diabetes, helping to better manage post-meal glucose levels and improve overall treatment outcomes.
  

The insulin delivery devices market research report includes in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 - 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Insulin delivery devices
  • Insulin pumps
    • Tubed pumps
    • Tubeless pumps
  • Pens
    • Reusable
    • Disposable
  • Other insulin delivery devices
• Consumables  
  • Testing strips
  • Pen needles
    • Standard
    • Safety
  • Syringes
  • Insulin pumps consumables

Market, By End Use

• Hospitals and Clinics
• Home care
• Other end use

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea

• Latin America
  • Brazil
  • Mexico
  • Argentina

• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE